Background: D-Dimer testing is sensitive but not specific for diagnosing deep venous thrombosis (DVT). Changing the use of testing and the threshold level for a positive test result on the basis of risk for DVT might improve the tradeoff between sensitivity and specificity and reduce the need for testing.
A
s currently used, D-dimer testing is sensitive but not specific for diagnosing deep venous thrombosis (DVT). A negative result (D-dimer level Ͻ0.5 g/mL) excludes the diagnosis (1), but a positive result (Ն0.5 g/ mL) mandates additional testing, usually venous ultrasonography. To improve the tradeoff between D-dimer sensitivity and specificity, it may make sense to vary the threshold distinguishing a negative from a positive test result on the basis of patients' probability of having DVT.
Prevalence of DVT is low in patients with a low clinical pretest probability (C-PTP), so use of a higher, lesssensitive threshold might exclude DVT in more patients without an unacceptable increase in the number of missed diagnoses; we previously showed in a retrospective analysis that using a higher D-dimer cutoff in patients with low C-PTP for venous thromboembolism (VTE) increased test specificity from 54% to 95% while maintaining a negative predictive value of 98% (2) . Conversely, DVT prevalence is high in patients with high C-PTP, and most hospitalized patients (regardless of C-PTP) have elevated D-dimer levels due to other comorbid conditions (for example, cancer, infection, or surgery). In these patients, results of D-dimer testing will rarely be negative and use of the test is likely to be uninformative.
With these considerations in mind, we designed and conducted a trial to determine whether a D-dimer testing strategy that uses a threshold in outpatients with low C-PTP that is higher than that used in outpatients with moderate C-PTP and that omits D-dimer testing in outpatients with high C-PTP and all inpatients is as safe as (that is, misses a similar number of DVT events) using a single threshold for all patients and reduces the number of tests required to exclude a first suspected DVT.
Setting and Participants
Consecutive outpatients and inpatients aged 18 years or older who presented with a suspected first symptomatic DVT to outpatient clinics, emergency departments, and inpatient wards were prospectively assessed for enrollment (Appendix Figure 1 , available at www.annals.org). Patients were excluded if they received full-dose heparin for 24 hours or more before study entry; if other tests for DVT had already been done; or if they had an ongoing requirement for anticoagulation, presented with symptoms consistent with pulmonary embolism (PE), were asymptomatic within 7 days of presentation, had a previous DVT or PE, had an expected survival of less than 3 months, or were pregnant or geographically inaccessible for follow-up. The study protocol was approved by the institutional review board of each participating center and is consistent with the principles of the Declaration of Helsinki.
Randomization
After informed written consent was provided and before any diagnostic testing, a clinician (research nurse, research assistant, or physician) used the 9-point Wells clinical prediction rule (Appendix Table 1 , available at www .annals.org) to categorize the patient's C-PTP of DVT as low, moderate, or high (3). The clinician was not permitted to assign a C-PTP that differed from the prediction rule.
A biostatistician created a computer-generated 1:1 randomization sequence stratified by inpatient or outpatient status and clinical center. Study groups were allocated using a centralized automated center that, after a call from a research nurse or assistant, recorded participants' inpatient or outpatient status and C-PTP and assigned the participant to a study group. Patients enrolled within 72 hours of being hospitalized who had leg symptoms present at admission were classified as outpatients.
Study personnel were not precluded from knowing the randomly assigned group but were blinded to the quantitative D-dimer levels (that is, test results were reported qualitatively as positive or negative). Radiologists, ultrasonographers, and study adjudicators were all blinded to group allocation. Data analysts for the trial were unblinded to group allocation at final analysis. Laboratory personnel were also notified of the study group assignment so that the appropriate D-dimer cutoff could be applied.
Interventions Uniform Testing (Control Testing)
All control patients had D-dimer testing. Results of the D-dimer assay were reported as negative if the D-dimer level was less than 0.5 g/mL and positive if the level was 0.5 g/mL or higher. If the results were negative, no further diagnostic testing was performed and anticoagulant therapy was withheld. If the results were positive, participants had ultrasonography of the proximal veins of the symptomatic leg. Patients with low C-PTP and a normal ultrasonogram had no further diagnostic testing, and anticoagulant therapy was withheld. Patients with moderate or high C-PTP and a normal ultrasonogram had repeated ultrasonography of the same leg 6 to 8 days later (Figure and 
Selective Testing (Experimental Strategy)
Outpatients with low or moderate C-PTP had D-dimer testing. Outpatients with high C-PTP and all inpatients skipped D-dimer testing and had ultrasonography of the proximal veins of the symptomatic leg. For outpatients with low C-PTP, the results of the D-dimer assay were reported as negative if the D-dimer level was less than 1.0 g/mL and positive if the level was 1.0 g/mL or more. For outpatients with moderate C-PTP, the results were reported as negative if the D-dimer level was less than 0.5 g/mL and positive if the level was 0.5 g/mL or more.
If the results were negative, no further diagnostic testing was performed and anticoagulant therapy was withheld. If the results were positive, patients had ultrasonography of the proximal veins of the symptomatic leg. Patients with low C-PTP and a normal ultrasonogram had no further diagnostic testing, and anticoagulant therapy was withheld. Patients with moderate or high C-PTP and a normal ultrasonogram had repeated ultrasonography 6 to 8 days later (Figure) . 
D-Dimer Assays

Contribution
This trial compared D-dimer testing of all patients with D-dimer testing based on clinical pretest probability among patients with suspected first DVT. Selective testing based on probability identified equal proportions of patients with DVT and substantially reduced the number of D-dimer assays and ultrasonographies performed.
Caution
Patients and study personnel were not blinded to trial interventions.
Implication
A D-dimer testing strategy based on DVT probability is as safe as and more efficient than testing everyone.
-The Editors
Original Research Selective D-Dimer Testing clinical laboratory at the Jewish General Hospital (Montreal, Québec, Canada). The MDA D-dimer assay (bioMérieux, Durham, North Carolina, and Trinity Biotech, County Wicklow, Ireland) was used for the first 1237 patients, but production of the assay was discontinued by the manufacturer. The STA-Liatest D-Di (Diagnostica Stago, Asnières, France) was used for the remaining patients. These assays showed similar operating characteristics when compared using stored blood samples from a previous unpublished study by our group. The D-dimer cutoff of 1.0 g/mL was selected on the basis of the results of a previous retrospective analysis (2) . Laboratory personnel were informed about study group allocation so that they could report D-dimer assay results as positive or negative, but quantitative results were not provided to the clinical centers.
Ultrasonography
Compression ultrasonography was performed at 1-cm intervals from the common femoral vein to the calf trifurcation; calf veins below the trifurcation were not assessed. The sole criterion for diagnosis of DVT was inability to fully compress the lumen of the deep veins with application of ultrasonography probe pressure.
Outcomes and Follow-up
All randomly assigned patients, including those treated for DVT after initial testing, were followed for 3 months. Patients who presented with symptoms of suspected DVT had venous ultrasonography of the proximal veins followed by repeated ultrasonography after 6 to 8 days if the first one was normal (Appendix, available at www.annals.org). Patients with suspected PE had a ventilation-perfusion scan or spiral computed tomography of the pulmonary arteries followed by serial bilateral ultrasonography of the proximal veins if the lung imaging test was nondiagnostic. D-Dimer testing was not performed as part of evaluation for suspected VTE during follow-up.
Primary outcomes were the proportion of patients not diagnosed with DVT during initial testing who had objectively confirmed symptomatic VTE (proximal DVT or PE) during 3-month follow-up and the proportion of patients undergoing D-dimer testing and ultrasonography. Secondary outcomes were suspected major bleeding events and deaths. Thromboembolic events, bleeding events, and deaths were evaluated using predefined criteria by a central adjudication committee that was blinded to allocation (Appendix).
Statistical Analysis
We estimated that 1% of patients who had no DVT on initial testing would develop VTE during 3-month follow-up in each group and calculated a sample size that would yield an upper CI less than 2%, a "missed DVT" rate considered acceptable because it is the proportion seen when DVT is excluded using venography (the reference standard diagnostic test for DVT) (4). We estimated that randomly assigning 1000 patients per group would yield a 95% CI of 0.4% to 1.9% for the proportion of patients with no DVT on initial testing who would develop VTE and a 95% CI of approximately 1% in each direction for the between-group difference in events. On the basis of data from the literature (5-7) and the results of a local audit, we assumed that 66% of participants would be outpatients (low C-PTP, 50%; moderate C-PTP, 35%; and high C-PTP, 15%) and 33% would be inpatients (low C-PTP, 30%; moderate C-PTP, 60%; and high C-PTP, 10%).
Patients were analyzed in the groups they were randomly assigned (intention to treat), and patients lost to follow-up were excluded (Figure) . The data safety monitor performed unblinded interim analyses after enrollment of 500, 1000, and 1500 patients to ensure that VTE during follow-up did not exceed predefined acceptable levels. The results were not released to trial investigators or data analysts. We performed prespecified subgroup analyses of trial outcomes in outpatients with low C-PTP because the D-dimer threshold in this group was increased from the standard threshold in the selective strategy group, and we report between-group differences in the D-dimer range between 0.5 and 1.0 g/mL. We calculated exact binomial 95% CIs for proportions and used the modified Wilson score method for differences between proportions.
Data analyses were performed by biostatisticians using SAS, version 9.1 (SAS Institute, Cary, North Carolina), and StatXact 6 (Cytel, Cambridge, Massachusetts).
Role of the Funding Source
This trial was funded by the Heart and Stroke Foundation of Ontario. The funding source had no role in data collection, analysis, or interpretation of the data; the writing of the report; or the decision to submit for publication.
RESULTS
Of 1723 patients enrolled, 863 were randomly assigned to uniform testing and 860 to selective testing (Table 1); 1542 (89%) were outpatients, and 181 (11%) were inpatients. After reaching 86% of the target sample size and recognizing that accrual was slow and more outpatients had been enrolled than had been originally planned, the trial steering committee decided to stop enrollment in January 2010.
Uniform Testing
Of 863 patients randomly assigned to uniform testing, 772 were outpatients (low C-PTP, 334; moderate C-PTP, 319; and high C-PTP, 119) and 91 were inpatients (Table 1, Figure, and Appendix Figure 2) . Results of D-dimer testing were positive in 506 patients (418 outpatients and 88 inpatients) and negative in 353 patients (351 outpatients and 2 inpatients), and 4 patients did not have the test (Figure) . Fifty-six patients with positive results were diagnosed with DVT by ultrasonography during initial testing, comprising 11.1% of the 506 patients with positive results on D-dimer testing and 6.5% of 863 patients (Appendix Table 2 , available at www.annals.org); none of the 81 outpatients with low C-PTP and a D-dimer level between 0.5 and 1.0 g/mL had DVT on ultrasonography. None of the 353 patients with negative results on D-dimer testing had additional diagnostic testing. Nine patients (2 D-dimer-positive patients, 6 D-dimer-negative patients, and 1 patient who did not have D-dimer testing) were lost to follow-up after initial testing.
Four patients had VTE diagnosed during follow-up, comprising 0.8% (95% CI, 0.2% to 2.0%) of the 506 patients with positive results on D-dimer testing who had a normal ultrasonogram on initial testing and 0.5% (CI, Original Research Selective D-Dimer Testing 0.1% to 1.3%) of the 798 patients who did not have DVT diagnosed on initial testing and who remained in the sample at 3-month follow-up. None of the 4 events were in outpatients with low C-PTP and D-dimer levels between 0.5 and 1.0 g/mL. No patient with a negative result on D-dimer testing had VTE diagnosed during follow-up (0.0% [CI, 0.0% to 1.1%]) ( Table 2 and Appendix Table  3 , available at www.annals.org).
One patient with high C-PTP, a positive result on D-dimer testing, and no VTE had a major bleeding event, and 15 patients died of causes unrelated to VTE (14 of progressive cancer and 1 of cardiac failure). Of the 863 patients, 859 (99.5%) had D-dimer testing, 505 (58.5%) had initial ultrasonography, and 334 (38.7%) had repeated ultrasonography after 6 to 8 days.
Selective Testing
Of 860 patients randomly assigned to selective testing, 770 were outpatients (low C-PTP, 360; moderate C-PTP, 310; and high C-PTP, 100) and 90 were inpatients (Table 3 and Figure) . Of the 360 outpatients with low C-PTP, results of D-dimer testing were negative in 288 patients (80%) and positive in 72 patients (Figure) . Of 288 Ddimer-negative patients (D-dimer level Ͻ0.5 g/mL in 200 and 0.5 to 1.0 g/mL in 88), none developed VTE during follow-up (0.0% [CI, 0.0% to 1.3%]) and 1 was lost to follow-up. Of the 72 D-dimer-positive patients, 8 (11%) were diagnosed with DVT by ultrasonography during initial testing (Appendix Table 2 ) and none with normal ultrasonograms developed VTE during follow-up (0.0% [CI, 0.0% to 5.1%]).
Of 310 outpatients with moderate C-PTP, 132 had negative results on D-dimer testing (43%), 176 had positive results, and 2 did not have D-dimer testing. Of 132 D-dimer-negative patients, 1 developed VTE during follow-up (0.8% [CI, 0.0% to 4.3%]) and 5 were lost to follow-up. Of 176 D-dimer-positive patients, 23 (13%) were diagnosed with DVT by ultrasonography during initial testing (Appendix Table 2 ). One of the 153 patients with a positive result on D-dimer testing and a normal ultrasonogram developed VTE during follow-up (0.6%
[CI, 0.0% to 3.2%]) and 4 were lost to follow-up ( Table 2) .
Of 100 outpatients with high C-PTP and the 90 inpatients, 20 (10.5%) were diagnosed with DVT during initial testing (Appendix Table 2 ). Two patients with normal ultrasonograms had VTE during follow-up (1.1% [CI, 0.1% to 3.8%]) ( Table 2 and Figure) , and 1 was lost to follow-up. Of the 860 patients, 51 (5.9%) were therefore diagnosed with DVT during initial testing and 4 (0.5% [CI, 0.1% to 1.3%]) who were not diagnosed with DVT during initial testing developed VTE during follow-up ( Table 2) .
Two patients had major bleeding events (1 with high C-PTP and a negative result on D-dimer testing and 1 with moderate C-PTP and a positive result on D-dimer testing); neither patient had VTE or had received anticoagulant therapy. Fifteen patients died of causes unrelated to VTE CFV ϭ common femoral vein; C-PTP ϭ clinical pretest probability; DVT ϭ deep venous thrombosis; PE ϭ pulmonary embolism; SFV ϭ superficial femoral vein. * All VTEs during follow-up occurred in outpatients. Appendix Table 3 (available at www.annals.org) shows the distribution and timing of VTE during follow-up in patients diagnosed with DVT during initial testing. † 1 patient (moderate C-PTP, positive results on D-dimer testing, and normal ultrasonogram) was diagnosed with incidental PE on a staging computed tomographic scan for lymphoma the day after study enrollment and received anticoagulant therapy; this was not classified as an event because PE was not clinically suspected. ‡ Sudden death (fatal PE could not be excluded). (10) 21 (13) 58 (7) 8 (2) 27 (8) 23 (13) 58 (6.7) Paralysis/paresis or casting of a limb, n (%)
3 (1) 15 (4) 4 (3) 21 (2) 7 (2) 9 (2) 7 (4) 23 (3) Recent surgery/bedridden, n (%) 17 (5) 59 (17) 82 (52) 158 (18) 17 (5) 54 (16) 79 (44) 150 (17) C-PTP ϭ clinical pretest probability. * C-PTP categories include inpatients who underwent testing in the selective testing group as if they were at high risk but who may have had low, moderate, or high C-PTP. † Receiving ongoing treatment or palliative care or having received treatment within the previous 6 mo.
Original Research (13 of progressive cancer, 1 of cardiac failure, and 1 of septic shock). Of the 860 patients, 668 (77.7%) had D-dimer testing, 438 (50.9%) had initial ultrasonography, and 383 (44.5%) had repeated ultrasonography after 6 to 8 days.
Comparison of the Testing Strategies
The between-group difference in the number of VTE events during follow-up was 0.0 percentage point (CI, Ϫ0.8 to 0.8 percentage point) in patients not diagnosed with DVT during initial testing and Ϫ0.3 percentage point (CI, Ϫ1.8 to 0.8 percentage points) (favoring selective testing) in the outpatient or low C-PTP subgroup (Table 3). The between-group difference in the proportion of patients undergoing testing was Ϫ21.8 percentage points (CI, Ϫ24.8 to Ϫ19.1 percentage points) for D-dimer testing and Ϫ7.6 percentage points (Ϫ12.2 to Ϫ2.9 percentage points) for ultrasonography, both favoring selective testing ( Table 3) .
In the outpatient and low C-PTP subgroup, the proportion of patients who had ultrasonography was 20.0% in the selective D-dimer group and 41.0% in the uniform D-dimer group (difference of Ϫ21.0 percentage points, favoring selective testing [CI, Ϫ27.6 to Ϫ14.2 percentage points]) ( Table 3) .
Twenty-four patients (17 in the uniform group and 7 in the selective group) received therapeutic anticoagulation during follow-up for reasons other than VTE, most commonly superficial phlebitis (13 in the uniform group and 4 in the selective group). Off-protocol ultrasonography below the calf vein trifurcation was performed in some patients at 1 center, leading to diagnosis and treatment of isolated distal DVT in 5 patients in the uniform group, 4 at the time of initial testing (not reported as initial DVT) and 1 during follow-up (adjudicated as not a study outcome). Removing these 24 patients from the denominator for the primary outcome measure did not change the trial results (0.50% of the selective group and 0.51% of the uniform group had VTE during follow-up).
DISCUSSION
In this trial comparing uniform with selective D-dimer testing in patients with suspected first DVT, a selective strategy-which used a higher D-dimer threshold to exclude first acute DVT in outpatients with low C-PTP and omitted D-dimer testing in outpatients with high C-PTP and all inpatients-was as safe as and more efficient than the uniform testing strategy, which used the same threshold to exclude DVT in all patients. The frequency of VTE during the 3-month follow-up did not differ between groups, with confidence bounds surrounding the estimate of no difference well below the clinically significant VTE event rate of 2%. The 2% event rate is considered an acceptable threshold because it is the rate seen when DVT is excluded by venography, the reference standard test for DVT (4) . The selective strategy was more efficient insofar as an absolute 21.8% fewer patients required D-dimer testing and 7.7% fewer required ultrasonography compared with uniform testing. Finally, the 2 diagnostic strategies resulted in a similar proportion of patients being diagnosed with VTE during initial testing. Using a D-dimer threshold of 1.0 g/mL rather than 0.5 g/mL to exclude DVT in outpatients with low C-PTP halved the number of those who required ultrasonography. This savings, which corresponded to 10% of all patients in the selective group, accounted for the overall reduction in ultrasonography in this randomly assigned group. Of note, none of the patients with D-dimer levels between 0.5 and 1.0 g/mL (88 patients in the selective group and 81 patients in the uniform group) were diagnosed with VTE during initial testing or follow-up (0% [CI, 0.0% to 2.2%]), which confirms the safety of this approach.
The efficiency of the selective testing strategy was also improved by omitting D-dimer testing in outpatients with high C-PTP and in all inpatients despite the requirement for all of these patients to have ultrasonography. This finding occurred because only 15% of outpatients with high C-PTP and 2% of inpatients in the uniform group had DVT excluded by a negative result on D-dimer testing. Our finding that D-dimer testing is inefficient in these patient subgroups because most have a positive result is consistent with reports published after our study began (8 -11) .
A search of PubMed from 1975 to 2012 using the Medical Subject Heading terms deep vein thrombosis, diagnosis, fibrin fibrinogen degradation products, venous thrombosis/ultrasonography, and clinical trial retrieved no other trials that prospectively evaluated using a higher D-dimer level to exclude venous thrombosis in patients with low C-PTP than that used in patients with moderate or high C-PTP. Therefore, to our knowledge, this trial is the first to point toward selective D-dimer testing as a safe and efficient testing strategy in patients with suspected first DVT.
Previous retrospective analyses of patients with suspected PE (2, 12, 13) and DVT (2, 14) reported that using a higher D-dimer threshold in patients with low C-PTP resulted in a substantially increased proportion of patients with negative results on D-dimer testing and retained a high negative predictive value (99% [12] , 95% [13] , and 98% [14] ) despite a decrease in sensitivity. Schouten and colleagues (15) have similarly proposed that using agespecific D-dimer levels in patients with low C-PTP of DVT may also reduce the need for ultrasonography.
Our study has several limitations. The results may not be generalizable to patients with a history of DVT or to other D-dimer tests, although retrospective analyses suggest consistent findings with other assays (2, (12) (13) (14) . As with other recent studies, the overall prevalence of DVT in the current study was low at 7.1% (5). This probably reflects heightened awareness of VTE and a lower threshold for diagnostic referral. However, this finding also highlights the need for diagnostic strategies that efficiently exclude thrombosis in low-prevalence populations.
Study personnel were not blinded to results of ultrasonography or D-dimer testing or management allocation, which could have biased assessment for suspected VTE during follow-up. However, this bias was reduced because study personnel were blinded to the quantitative D-dimer level so that they did not know whether a negative result was less than 0.5 g/mL or between 0.5 and 1.0 g/mL. It became evident during the study that the specificity and efficiency of D-dimer testing was very low for inpatients (8 -11) , which led to fewer enrolled inpatients than expected and a lower total enrollment than originally planned. However, power was not reduced in outpatients, because we enrolled more patients in this subgroup than we had expected.
In summary, this study supports the use of a higher D-dimer threshold to exclude first DVT in outpatients with low C-PTP than that used in outpatients with moderate C-PTP and that D-dimer testing should be avoided in outpatients with high C-PTP and in all inpatients. Future studies to determine whether this diagnostic strategy can be applied to patients who present with suspected recurrent DVT or PE are required.
